Capital Bank & Trust Co acquired a new stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 189,860 shares of the biopharmaceutical company’s stock, valued at approximately $8,517,000. Capital Bank & Trust Co owned 0.17% of Juno Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Teachers Advisors LLC grew its position in Juno Therapeutics by 15.4% in the second quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock valued at $2,219,000 after acquiring an additional 9,890 shares during the period. DekaBank Deutsche Girozentrale grew its position in Juno Therapeutics by 27.9% in the third quarter. DekaBank Deutsche Girozentrale now owns 61,900 shares of the biopharmaceutical company’s stock valued at $1,712,000 after acquiring an additional 13,500 shares during the period. Northern Trust Corp grew its position in Juno Therapeutics by 11.8% in the second quarter. Northern Trust Corp now owns 382,631 shares of the biopharmaceutical company’s stock valued at $11,438,000 after acquiring an additional 40,468 shares during the period. Candriam Luxembourg S.C.A. bought a new stake in Juno Therapeutics in the third quarter valued at $5,428,000. Finally, Sivik Global Healthcare LLC bought a new stake in Juno Therapeutics in the third quarter valued at $2,467,000. Institutional investors and hedge funds own 70.37% of the company’s stock.

Shares of Juno Therapeutics, Inc. (JUNO) opened at $58.65 on Monday. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics, Inc. has a 1-year low of $17.52 and a 1-year high of $63.45.

Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.07. The company had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.57) earnings per share. equities analysts predict that Juno Therapeutics, Inc. will post -4.02 earnings per share for the current year.

In other news, General Counsel Bernard J. Cassidy sold 28,000 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the transaction, the general counsel now owns 55,970 shares of the company’s stock, valued at $2,514,172.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert Azelby sold 12,850 shares of the company’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $44.95, for a total value of $577,607.50. Following the transaction, the executive vice president now directly owns 37,439 shares in the company, valued at approximately $1,682,883.05. The disclosure for this sale can be found here. Insiders have sold 54,801 shares of company stock worth $2,527,741 in the last 90 days. Company insiders own 15.08% of the company’s stock.

A number of brokerages have weighed in on JUNO. Maxim Group reiterated a “buy” rating and issued a $56.00 price target on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Cowen reiterated a “buy” rating and issued a $49.00 price target on shares of Juno Therapeutics in a research report on Friday, October 27th. Wedbush reiterated an “outperform” rating and issued a $64.00 price target (up from $42.00) on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Leerink Swann reiterated an “in-line” rating and issued a $56.00 price target (up from $34.00) on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Finally, Barclays began coverage on Juno Therapeutics in a research report on Wednesday, September 6th. They issued an “overweight” rating and a $55.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company. Juno Therapeutics currently has an average rating of “Hold” and a consensus target price of $45.48.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/11/capital-bank-trust-co-acquires-new-stake-in-juno-therapeutics-inc-juno.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Stock Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related stocks with our FREE daily email newsletter.